Essentra Completes Acquisition of Clondalkin SPD

Published: February 19, 2015

MILTON KEYNES, UK | Essentra has completed its $455m acquisition of Clondalkin SPD, a deal said to transform it into a global leader in pharmaceutical and beauty specialist packaging. The company says the deal opens up the US, the world’s largest pharmaceutical and beauty packaging market, to Essentra as well as boosting its existing presence across Europe.

The pharmaceutical and beauty packaging sector was estimated at $50bn in 2011 and is forecast to reach $79bn by 2018.

The acquisition adds 2,400 people in 24 facilities, including nine in North America as well as in the UK, Ireland, Spain, Poland, and the Netherlands, to Essentra’s existing network. The acquisition will also broaden the suite and flexibility of services Essentra can offer, complementing its existing portfolio of folding cartons, product literature, labels, foil, tapes, and authentication capabilities.

Clondalkin SPD’s customer base includes the leading global pharmaceutical and health and personal care companies, and half of its revenues come from its operations in the US.

Malcolm Waugh, managing director, Health & Personal Care Packaging, at Essentra, says, “The combination of Essentra’s existing packaging capabilities with Clondalkin’s Specialist Packaging Division is a great example of our ambition to expand our capabilities in attractive end-markets, both geographically and from a product perspective. Bringing together the knowledge, expertise and skills from our combined network represents a fantastic opportunity to respond even better to our customers’ needs, and I am very excited to be leading the team going forward.”

The resulting scale and breadth of Essentra’s Health & Personal Care Packaging activities has led to the creation of a separate business unit.

This email address is being protected from spambots. You need JavaScript enabled to view it.